Hunter syndrome

Mendelian MONDO:0010674 Pathograph 29 Mucopolysaccharidosis Lysosomal storage diseases X-linked genetic disorders

Hunter syndrome, also called mucopolysaccharidosis type 2 (MPS II), is an X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase (IDS). Failure to degrade dermatan sulfate and heparan sulfate produces progressive glycosaminoglycan accumulation in lysosomes and extracellular matrix. The resulting lysosomal dysfunction drives neuronopathic central nervous system disease, connective-tissue and skeletal-muscle involvement, airway obstruction, hepatosplenomegaly, and cardiac valve thickening. The clinical spectrum ranges from attenuated disease with preserved cognition to severe early-onset disease with progressive cognitive impairment.

Ask OpenScientist

Ask a research question about Hunter syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
8
Pathophys.
12
Phenotypes
29
Pathograph
1
Genes
3
Treatments
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0010674 mucopolysaccharidosis type 2
skos:exactMatch MONDO
👪

Inheritance

1
X-linked recessive inheritance HP:0001419
Hunter syndrome is the canonical X-linked recessive mucopolysaccharidosis and predominantly affects hemizygous males, although rare affected females have been reported.
X-linked recessive inheritance
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"The disease is a X-linked condition affecting males and rarely females, clinically divided into severe (2/3) and attenuated types."
This review abstract directly supports the canonical X-linked recessive inheritance pattern and the familiar severe-versus-attenuated clinical framing used for Hunter syndrome.
⚙

Pathophysiology

8
Iduronate-2-sulfatase deficiency
Pathogenic IDS variants reduce or abolish iduronate-2-sulfatase activity, blocking normal lysosomal degradation of dermatan sulfate and heparan sulfate.
IDS link
glycosaminoglycan catabolic process link ↓ DECREASED
iduronate-2-sulfatase activity link ↓ DECREASED
Downstream
Heparan sulfate and dermatan sulfate lysosomal accumulation IDS deficiency directly causes progressive intracellular storage of its glycosaminoglycan substrates.
Iduronate-2-sulfatase activity The IDS enzymatic lesion is measured diagnostically as deficient iduronate-2-sulfatase activity in patient cells or plasma.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Hunter syndrome is caused by deficiency of the lysososmal enzyme iduronate-2-sulphatase that cleaves O-linked sulphate moieties from dermatan sulphate and heparan sulphate and leads to accumulation of GAGs."
This abstract states the proximal IDS enzyme defect and directly links it to blocked dermatan sulfate and heparan sulfate degradation.
Heparan sulfate and dermatan sulfate lysosomal accumulation
IDS insufficiency leads to excess heparan sulfate and dermatan sulfate within lysosomes across multiple tissues and organs, creating the primary storage burden that initiates downstream disease biology.
lysosome link
Downstream
Lysosomal dysfunction Persistent substrate storage disrupts lysosomal homeostasis and produces broader cellular dysfunction.
Hepatosplenomegaly Visceral glycosaminoglycan storage contributes to enlarged liver and spleen volume.
Urinary glycosaminoglycans Quantitative urinary glycosaminoglycan excretion is a diagnostic and pharmacodynamic readout of the systemic storage burden.
CSF heparan sulfate Heparan sulfate is elevated in CSF in neuronopathic MPS II and reflects central nervous system substrate accumulation.
CSF dermatan sulfate Dermatan sulfate is also elevated in CSF in neuronopathic MPS II and reports the second primary IDS substrate.
Show evidence (1 reference)
PMID:21518713 SUPPORT Human Clinical
"Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by insufficiency of the iduronate-2-sulfatase enzyme, which results in excess heparan and dermatan sulfates within the lysosomes of various tissues and organs, including the central nervous system."
This natural-history abstract directly supports lysosomal storage of heparan sulfate and dermatan sulfate as the core upstream lesion.
Lysosomal dysfunction
Storage burden progresses beyond primary glycosaminoglycan accumulation to broader lysosomal dysfunction, including glial lysosomal aggregation in IDS-deficient neural cells and evidence of abnormal lysosomal lipid burden in neuronopathic patients.
astrocyte link
autophagy link ↓ DECREASED
Downstream
Secondary neuronal injury Persistent lysosomal dysfunction is associated with measurable neuronal damage and degeneration in neuronopathic disease.
CSF GM3 ganglioside GM3 ganglioside elevation in CSF reports secondary lysosomal lipid storage and dysfunction in the neuronopathic CNS branch.
Connective tissue and skeletal-muscle dysfunction Storage-driven cellular dysfunction propagates into joints, cartilage, growth plates, and connective tissue.
Airway soft-tissue disease Soft-tissue storage and thickening drive progressive upper airway disease.
Cardiac valvular thickening and dysfunction Persistent glycosaminoglycan burden disrupts valve extracellular matrix homeostasis and drives valvular disease.
Show evidence (2 references)
PMID:24201805 SUPPORT In Vitro
"Experiments here reported show that NSCs derived from the subventricular zone (SVZ) of early symptomatic IDS-knockout (IDS-ko) mouse retained self-renewal capacity in vitro, but differentiated earlier than wild-type (wt) cells, displaying an evident lysosomal aggregation in oligodendroglial and..."
This in vitro IDS-knockout neural stem cell model shows direct lysosomal aggregation in glial lineages, supporting secondary lysosomal dysfunction downstream of substrate storage.
PMID:32707880 SUPPORT Human Clinical
"In addition to the accumulation of CSF GAGs, nMPS II patients show elevated levels of lysosomal lipids, neurofilament light chain, and other biomarkers of neuronal damage and degeneration."
Patient biomarker data show that primary storage is accompanied by lysosomal dysfunction in neuronopathic MPS II.
Secondary neuronal injury
In neuronopathic MPS II, lysosomal dysfunction is accompanied by measurable biomarkers of neuronal damage and degeneration, establishing a distinct downstream neuroinjury step before overt clinical CNS decline.
neuron link
Downstream
Neuronopathic central nervous system dysfunction Secondary neuronal injury contributes to progressive cognitive and motor decline in severe disease.
Neurofilament light chain Elevated neurofilament light chain in CSF and serum reports axonal injury and active neurodegeneration in neuronopathic MPS II.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"In addition to the accumulation of CSF GAGs, nMPS II patients show elevated levels of lysosomal lipids, neurofilament light chain, and other biomarkers of neuronal damage and degeneration."
This patient biomarker study supports a separate downstream step of neuronal damage and degeneration after lysosomal dysfunction.
Neuronopathic central nervous system dysfunction
Severe Hunter syndrome causes progressive central nervous system disease with decline in cognitive, language, adaptive, and motor functions rather than stable neurodevelopment.
neuron link astrocyte link
Downstream
Cognitive impairment The severe neuronopathic form manifests clinically as progressive cognitive impairment.
Hydrocephalus Communicating hydrocephalus is a recognized CNS manifestation that can accompany macrocephaly in MPS II.
Show evidence (2 references)
PMID:21518713 SUPPORT Human Clinical
"One subset of patients had normal cognitive, speech and language, and adaptive functions whereas the other showed a dramatic decline in these areas."
This natural-history study shows the neuronopathic subgroup has progressive central nervous system dysfunction rather than stable cognition.
PMID:19597960 SUPPORT Human Clinical
"Patients with the severe form of the disease have cognitive impairment and typically die in the second decade of life."
This large Hunter Outcome Survey review supports clinically meaningful severe neuronopathic disease with cognitive impairment and worse outcome.
Connective tissue and skeletal-muscle dysfunction
Accumulated glycosaminoglycans in joints, cartilage, and connective tissue drive progressive stiffness, growth impairment, and skeletal pathology.
chondrocyte link
Downstream
Joint stiffness Joint and connective-tissue GAG storage manifests clinically as progressive joint stiffness.
Short stature Skeletal and cartilage involvement contributes to growth impairment and short stature.
Macrocephaly Cranial skeletal involvement and communicating hydrocephalus can manifest as macrocephaly or large head circumference.
Spinal canal stenosis Skeletal and connective-tissue disease can narrow the spinal canal and cause spinal stenosis.
Carpal tunnel syndrome Connective-tissue thickening around the wrist can produce median nerve compression clinically recognized as carpal tunnel syndrome.
Show evidence (2 references)
PMID:20354449 SUPPORT Human Clinical
"Lysosomal accumulation of these GAG molecules results in cell, tissue, and organ dysfunction. The skeletal-muscle system involvement is because of essential accumulated GAGs in joints and connective tissue."
This Hunter syndrome review directly links substrate storage to the joint and connective-tissue pathology underlying short stature and stiffness.
PMID:38085235 SUPPORT Model Organism
"In contrast, tracheal, epiphyseal, and articular cartilage remained largely uncorrected by all vectors tested."
This MPS II model shows that cartilage remains a resistant downstream tissue compartment even when other peripheral pathology improves, matching the clinical stubbornness of skeletal disease.
Airway soft-tissue disease
Progressive rhinitis, noisy breathing, and sleep apnea reflect glycosaminoglycan storage in upper-airway soft tissues and related ENT structures.
Downstream
Sleep apnea Progressive airway disease evolves from rhinitis and noisy breathing to sleep apnea.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Recurrent and prolonged rhinitis with persistent nasal discharge are the first symptoms of airway disease that manifests itself as noisy breathing and later sleep apnea."
This disease-specific review abstract directly supports progressive airway soft-tissue disease leading to noisy breathing and sleep apnea.
Cardiac valvular thickening and dysfunction
Dermatan-sulfate-rich valve extracellular matrix accumulates glycosaminoglycans, producing progressive leaflet thickening, regurgitation, and stenosis.
Downstream
Cardiac valve disease Leaflet thickening and stiffening produce the structural cardiac valve phenotype.
Show evidence (2 references)
PMID:39440439 SUPPORT Human Clinical
"DS is a major component of the extracellular matrix of heart valves, which can be affected in MPS II."
This cardiac natural-history study directly links dermatan-sulfate-rich valve extracellular matrix biology to the valvular disease of Hunter syndrome.
PMID:25345092 SUPPORT Human Clinical
"valvular involvement, with progressive thickening and stiffening of the valve leaflets leading to mitral and aortic regurgitation and stenosis ."
This review abstract directly describes the downstream valvular phenotype produced by Hunter syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hunter syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Cardiovascular 2
Hepatosplenomegaly Hepatosplenomegaly (HP:0001433)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Inguinal and umbilical hernias occur caused by the disturbed structure of connective tissue and increased liver and spleen volume."
This disease-specific review supports hepatosplenomegaly as part of the visceral storage phenotype.
Cardiac valve disease Abnormal heart valve morphology (HP:0001654)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"valvular involvement, with progressive thickening and stiffening of the valve leaflets leading to mitral and aortic regurgitation and stenosis ."
This abstract directly supports progressive structural heart valve disease in Hunter syndrome.
Ear 1
Hearing impairment Hearing impairment (HP:0000365)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Children with severe form, diagnosed at 12-36 months, have coarse facial feature, short stature, joint stiffness, short neck, broad chest, large head circumference, watery diarrhea, skeletal changes, progressive and profound mental retardation, retinal degeneration' hearing loss, cardiomyopathy,..."
This review abstract explicitly includes hearing loss among the classic manifestations of severe Hunter syndrome.
Head and Neck 2
Coarse facial features Coarse facial features (HP:0000280)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Children with severe form, diagnosed at 12-36 months, have coarse facial feature, short stature, joint stiffness, short neck, broad chest, large head circumference, watery diarrhea, skeletal changes, progressive and profound mental retardation, retinal degeneration' hearing loss, cardiomyopathy,..."
This disease-specific review lists coarse facial features among the core early somatic manifestations of severe Hunter syndrome.
Macrocephaly Macrocephaly (HP:0000256)
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Additional findings in neuronopathic and non-neuronopathic MPS II include: short stature, macrocephaly with or without communicating hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel syndrome, and hepatosplenomegaly."
GeneReviews explicitly lists macrocephaly with or without communicating hydrocephalus among MPS II findings.
Musculoskeletal 2
Joint stiffness Joint stiffness (HP:0001387)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Children with severe form, diagnosed at 12-36 months, have coarse facial feature, short stature, joint stiffness, short neck, broad chest, large head circumference, watery diarrhea, skeletal changes, progressive and profound mental retardation, retinal degeneration' hearing loss, cardiomyopathy,..."
This abstract directly lists joint stiffness among the characteristic somatic manifestations of severe disease.
Spinal canal stenosis Spinal canal stenosis (HP:0003416)
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Additional findings in neuronopathic and non-neuronopathic MPS II include: short stature, macrocephaly with or without communicating hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel syndrome, and hepatosplenomegaly."
GeneReviews explicitly lists spinal stenosis among additional MPS II findings.
Nervous System 3
Hydrocephalus Hydrocephalus (HP:0000238)
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Additional findings in neuronopathic and non-neuronopathic MPS II include: short stature, macrocephaly with or without communicating hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel syndrome, and hepatosplenomegaly."
GeneReviews lists communicating hydrocephalus as a possible associated finding with macrocephaly in MPS II.
Sleep apnea Sleep apnea (HP:0010535)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Recurrent and prolonged rhinitis with persistent nasal discharge are the first symptoms of airway disease that manifests itself as noisy breathing and later sleep apnea."
This abstract directly supports sleep apnea as a downstream respiratory manifestation of progressive airway disease in Hunter syndrome.
Cognitive impairment Cognitive impairment (HP:0100543)
Show evidence (1 reference)
PMID:19597960 SUPPORT Human Clinical
"Patients with the severe form of the disease have cognitive impairment and typically die in the second decade of life."
This Hunter Outcome Survey review directly supports cognitive impairment as a defining feature of severe neuronopathic Hunter syndrome.
Growth 1
Short stature Short stature (HP:0004322)
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Children with severe form, diagnosed at 12-36 months, have coarse facial feature, short stature, joint stiffness, short neck, broad chest, large head circumference, watery diarrhea, skeletal changes, progressive and profound mental retardation, retinal degeneration' hearing loss, cardiomyopathy,..."
This review explicitly lists short stature as part of the severe Hunter phenotype.
Other 1
Carpal tunnel syndrome Constrictive median neuropathy (HP:0012185)
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Additional findings in neuronopathic and non-neuronopathic MPS II include: short stature, macrocephaly with or without communicating hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel syndrome, and hepatosplenomegaly."
GeneReviews explicitly lists carpal tunnel syndrome; HPO represents the syndrome as constrictive median neuropathy.
🧬

Genetic Associations

1
IDS (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_753ba7a6-cef5-4665-81e9-306e11c618c5-2018-02-21T110000.000Z SUPPORT Other
"IDS | HGNC:5389 | mucopolysaccharidosis type 2 | MONDO:0010674 | XL | Definitive"
ClinGen classifies the IDS-mucopolysaccharidosis type 2 gene-disease relationship as definitive with X-linked inheritance.
💊

Treatments

3
Idursulfase enzyme replacement therapy
Action: Pharmacotherapy NCIT:C15986
Agent: idursulfase ↗
Intravenous recombinant iduronate-2-sulfatase is the standard disease-modifying therapy for peripheral somatic disease. It lowers urinary glycosaminoglycans, reduces organomegaly, and can improve endurance, but treatment effects are incomplete and CNS disease is not corrected.
Mechanism Target:
RESTORES Iduronate-2-sulfatase deficiency — Recombinant IDS supplements the deficient lysosomal enzyme in peripheral tissues.
Show evidence (1 reference)
PMID:17185020 SUPPORT Human Clinical
"To evaluate the safety and explore the efficacy of idursulfase (recombinant human iduronate-2-sulfatase) treatment for mucopolysaccharidosis II (MPS II)."
The clinical trial identifies idursulfase as recombinant human IDS, supporting treatment replacement of the deficient enzyme.
INHIBITS Heparan sulfate and dermatan sulfate lysosomal accumulation — Enzyme replacement lowers peripheral glycosaminoglycan burden and reduces visceral storage.
Show evidence (1 reference)
PMID:17185020 SUPPORT Human Clinical
"Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001)."
The trial directly shows that idursulfase lowers glycosaminoglycan burden, supporting inhibition of the storage mechanism.
Show evidence (3 references)
PMID:17185020 SUPPORT Human Clinical
"Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001). Both liver and spleen volume were decreased at 24 weeks (P<0.01) and 48 weeks (P<0.001). The 6-minute walk test distance increased an average of 48..."
This phase I/II trial directly supports biochemical and somatic benefit from idursulfase therapy.
PMID:25231261 SUPPORT Human Clinical
"Although the present protocol of idursulfase administration may result efficacious in delaying the MPS II somatic disease progression at some extent, in this study we observed that several signs and symptoms did not improve during the therapy."
This independent long-term pediatric study supports a conservative treatment claim: idursulfase delays somatic progression, but responses are partial rather than globally corrective.
PMID:25345092 SUPPORT Human Clinical
"Current research is focused on pharmacological chaperones, gene therapy and substrate reduction therapy and therapies that, unlike Idursulfase, do cross the blood-brain barrier."
This review supports the clinically important limitation that standard intravenous idursulfase does not address CNS disease because it does not cross the blood-brain barrier.
Tividenofusp alfa-eknm enzyme replacement therapy
Action: Pharmacotherapy NCIT:C15986
Agent: tividenofusp alfa-eknm ↗
Tividenofusp alfa-eknm is a CNS-penetrant enzyme replacement therapy approved for MPS II, extending enzyme replacement to the neuronopathic disease branch that standard intravenous idursulfase does not adequately address.
Mechanism Target:
RESTORES Iduronate-2-sulfatase deficiency — CNS-penetrant enzyme replacement is intended to restore deficient iduronate-2-sulfatase activity beyond the peripheral compartment.
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Weekly enzyme replacement therapy (ERT) with infusions of idursulfase, a recombinant form of human I2S, or tividenofusp alfa-eknm, a CNS-penetrant ERT, are approved for individuals with MPS II."
GeneReviews identifies tividenofusp alfa-eknm as an approved CNS-penetrant ERT for MPS II.
INHIBITS Secondary neuronal injury — Brain-penetrant enzyme replacement is mechanistically directed at the CNS injury branch downstream of lysosomal storage.
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Weekly enzyme replacement therapy (ERT) with infusions of idursulfase, a recombinant form of human I2S, or tividenofusp alfa-eknm, a CNS-penetrant ERT, are approved for individuals with MPS II."
The CNS-penetrant designation supports linking this approved ERT to the neuronopathic injury branch.
INHIBITS Neuronopathic central nervous system dysfunction — CNS penetration directly addresses the neuronopathic branch that non-BBB-crossing idursulfase does not adequately treat.
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Weekly enzyme replacement therapy (ERT) with infusions of idursulfase, a recombinant form of human I2S, or tividenofusp alfa-eknm, a CNS-penetrant ERT, are approved for individuals with MPS II."
GeneReviews states that tividenofusp alfa-eknm is CNS penetrant and approved for individuals with MPS II.
Show evidence (1 reference)
PMID:20301451 SUPPORT Human Clinical
"Weekly enzyme replacement therapy (ERT) with infusions of idursulfase, a recombinant form of human I2S, or tividenofusp alfa-eknm, a CNS-penetrant ERT, are approved for individuals with MPS II."
GeneReviews supports tividenofusp alfa-eknm as an approved CNS-penetrant enzyme replacement therapy for MPS II.
Multidisciplinary supportive care
Action: supportive care MAXO:0000950
Hunter syndrome remains a high-burden multisystem disease even in treated adults, so ongoing respiratory, ENT/audiologic, orthopedic, cardiology, and surgical management is required alongside disease-directed therapy.
Target Phenotypes: Hearing impairment ↗ Sleep apnea ↗ Abnormal heart valve morphology ↗ Joint stiffness ↗ Hydrocephalus ↗ Spinal canal stenosis ↗ Carpal tunnel syndrome ↗
Show evidence (1 reference)
PMID:40598289 SUPPORT Human Clinical
"Overall, adult patients with neuronopathic and non-neuronopathic MPS II had a high disease burden and requirement for surgeries, emphasizing the need to continue multidisciplinary management and regular assessments in adulthood."
This Hunter Outcome Survey analysis supports ongoing symptom-directed, multidisciplinary management as a necessary component of care even in the modern treatment era.
🔬

Biochemical Markers

6
Iduronate-2-sulfatase activity (DECREASED)
Context: Enzyme activity assay in leukocytes, fibroblasts, or plasma is the diagnostic biochemical readout of IDS deficiency.
Pathograph Readouts
Readout Of Iduronate-2-sulfatase deficiency Negative Diagnostic
Decreased iduronate-2-sulfatase activity reports the root lysosomal enzyme defect in Hunter syndrome.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Definitive diagnosis is based on enzyme activity assay in leukocytes, fibroblasts or plasma."
The review supports enzyme activity assay as the definitive biochemical diagnostic readout.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Hunter syndrome is caused by deficiency of the lysososmal enzyme iduronate-2-sulphatase that cleaves O-linked sulphate moieties from dermatan sulphate and heparan sulphate and leads to accumulation of GAGs."
This abstract supports deficient iduronate-2-sulfatase as the primary biochemical lesion.
Urinary glycosaminoglycans (ABNORMAL)
Context: Urinary glycosaminoglycan excretion is used for screening and falls rapidly with idursulfase, making it both a diagnostic and pharmacodynamic storage readout.
Pathograph Readouts
Readout Of Heparan sulfate and dermatan sulfate lysosomal accumulation Positive Diagnostic
Abnormal urinary GAG excretion reports systemic glycosaminoglycan storage.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Sceening is by quantitative assessment of urinary GAGs excretion."
The review names quantitative urinary GAG excretion as the screening readout.
Readout Of Heparan sulfate and dermatan sulfate lysosomal accumulation Negative Pharmacodynamic
Falling urinary GAGs report treatment-lowered systemic storage burden.
Show evidence (1 reference)
PMID:17185020 SUPPORT Human Clinical
"Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001)."
The idursulfase trial directly supports urinary GAG reduction as a pharmacodynamic treatment readout.
Show evidence (1 reference)
PMID:25345092 SUPPORT Human Clinical
"Sceening is by quantitative assessment of urinary GAGs excretion."
This supports urinary GAGs as a Hunter syndrome biochemical screening readout.
CSF heparan sulfate (INCREASED)
Context: Heparan sulfate is markedly elevated in CSF from neuronopathic MPS II patients despite standard peripheral therapy.
Pathograph Readouts
Readout Of Heparan sulfate and dermatan sulfate lysosomal accumulation Positive Diagnostic
Elevated CSF heparan sulfate reports CNS substrate storage in neuronopathic disease.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B)."
Patient CSF measurements directly support elevated heparan sulfate.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B)."
This supports CSF heparan sulfate as an elevated neuronopathic MPS II biomarker.
CSF dermatan sulfate (INCREASED)
Context: Dermatan sulfate is markedly elevated in CSF from neuronopathic MPS II patients and complements heparan sulfate as an IDS-substrate readout.
Pathograph Readouts
Readout Of Heparan sulfate and dermatan sulfate lysosomal accumulation Positive Diagnostic
Elevated CSF dermatan sulfate reports CNS substrate storage in neuronopathic disease.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B)."
Patient CSF measurements directly support elevated dermatan sulfate.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B)."
This supports CSF dermatan sulfate as an elevated neuronopathic MPS II biomarker.
CSF GM3 ganglioside (INCREASED)
Context: GM3 ganglioside is a secondary lysosomal lipid biomarker elevated in CSF from neuronopathic MPS II patients and correlated with CSF heparan sulfate.
Pathograph Readouts
Readout Of Lysosomal dysfunction Positive Diagnostic
Elevated CSF GM3 reports secondary lysosomal lipid storage beyond primary GAG accumulation.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"Targeted analysis of GM3, BMP, and glucosylceramides shows that nMPS II patient CSF (regardless of therapy) have elevated levels of these lipids (Figure 7A,D,G), and that there is a strong correlation between HS and lipids levels in the CSF (Figure 7B,E,H)."
Targeted lipidomics supports GM3 as a secondary lysosomal dysfunction readout.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"Targeted analysis of GM3, BMP, and glucosylceramides shows that nMPS II patient CSF (regardless of therapy) have elevated levels of these lipids (Figure 7A,D,G), and that there is a strong correlation between HS and lipids levels in the CSF (Figure 7B,E,H)."
This supports CSF GM3 ganglioside elevation as a fluid biomarker of lysosomal dysfunction.
Neurofilament light chain (INCREASED)
Context: Neurofilament light chain is elevated in CSF and serum from neuronopathic MPS II patients and reports neuronal injury downstream of lysosomal dysfunction.
Pathograph Readouts
Readout Of Secondary neuronal injury Positive Diagnostic
Elevated neurofilament light chain reports active axonal injury and neurodegeneration in the CNS disease branch.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"We measured levels of Nf-L in the CSF and serum and found a significant elevation in Nf-L in both the CSF and serum of nMPS II patients regardless of their treatment regimen (Figure 8A,C), and that Nf-L levels positively correlated with CSF HS (Figure 8B)."
Patient CSF and serum data support neurofilament light chain as a neuronal injury readout.
Show evidence (1 reference)
PMID:32707880 SUPPORT Human Clinical
"We measured levels of Nf-L in the CSF and serum and found a significant elevation in Nf-L in both the CSF and serum of nMPS II patients regardless of their treatment regimen (Figure 8A,C), and that Nf-L levels positively correlated with CSF HS (Figure 8B)."
This supports neurofilament light chain as a fluid biomarker of neuronal injury in neuronopathic MPS II.
{ }

Source YAML

click to show 
name: Hunter syndrome
creation_date: '2026-04-14T20:10:00Z'
updated_date: '2026-05-20T14:55:39Z'
category: Mendelian
description: >-
  Hunter syndrome, also called mucopolysaccharidosis type 2 (MPS II), is an
  X-linked lysosomal storage disorder caused by deficiency of
  iduronate-2-sulfatase (IDS). Failure to degrade dermatan sulfate and heparan
  sulfate produces progressive glycosaminoglycan accumulation in lysosomes and
  extracellular matrix. The resulting lysosomal dysfunction drives
  neuronopathic central nervous system disease, connective-tissue and
  skeletal-muscle involvement, airway obstruction, hepatosplenomegaly, and
  cardiac valve thickening. The clinical spectrum ranges from attenuated disease
  with preserved cognition to severe early-onset disease with progressive
  cognitive impairment.
disease_term:
  preferred_term: Hunter syndrome
  term:
    id: MONDO:0010674
    label: mucopolysaccharidosis type 2
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010674
      label: mucopolysaccharidosis type 2
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Mucopolysaccharidosis
- Lysosomal storage diseases
- X-linked genetic disorders
synonyms:
- mucopolysaccharidosis type II
- mucopolysaccharidosis type 2
- MPS II
- iduronate-2-sulfatase deficiency
- Hunter's syndrome
inheritance:
- name: X-linked recessive inheritance
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >-
    Hunter syndrome is the canonical X-linked recessive mucopolysaccharidosis
    and predominantly affects hemizygous males, although rare affected females
    have been reported.
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is a X-linked condition affecting males and rarely females,
      clinically divided into severe (2/3) and attenuated types.
    explanation: >-
      This review abstract directly supports the canonical X-linked recessive
      inheritance pattern and the familiar severe-versus-attenuated clinical
      framing used for Hunter syndrome.
pathophysiology:
- name: Iduronate-2-sulfatase deficiency
  description: >-
    Pathogenic IDS variants reduce or abolish iduronate-2-sulfatase activity,
    blocking normal lysosomal degradation of dermatan sulfate and heparan
    sulfate.
  gene:
    preferred_term: IDS
    description: Encodes iduronate-2-sulfatase, the lysosomal hydrolase deficient in Hunter syndrome.
    modifier: ABNORMAL
    term:
      id: hgnc:5389
      label: IDS
  genes:
  - preferred_term: IDS
    term:
      id: hgnc:5389
      label: IDS
  molecular_functions:
  - preferred_term: iduronate-2-sulfatase activity
    modifier: DECREASED
    term:
      id: GO:0004423
      label: iduronate-2-sulfatase activity
  biological_processes:
  - preferred_term: glycosaminoglycan catabolic process
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hunter syndrome is caused by deficiency of the lysososmal enzyme
      iduronate-2-sulphatase that cleaves O-linked sulphate moieties from
      dermatan sulphate and heparan sulphate and leads to accumulation of GAGs.
    explanation: >-
      This abstract states the proximal IDS enzyme defect and directly links it
      to blocked dermatan sulfate and heparan sulfate degradation.
  downstream:
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    causal_link_type: DIRECT
    description: IDS deficiency directly causes progressive intracellular storage of its glycosaminoglycan substrates.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hunter syndrome is caused by deficiency of the lysososmal enzyme
        iduronate-2-sulphatase that cleaves O-linked sulphate moieties from
        dermatan sulphate and heparan sulphate and leads to accumulation of GAGs.
      explanation: >-
        The review abstract directly links the IDS enzymatic deficiency to
        dermatan/heparan sulfate substrate accumulation.
  - target: Iduronate-2-sulfatase activity
    causal_link_type: DIRECT
    description: >-
      The IDS enzymatic lesion is measured diagnostically as deficient
      iduronate-2-sulfatase activity in patient cells or plasma.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Definitive diagnosis is based on enzyme activity assay in leukocytes, fibroblasts or plasma.
      explanation: >-
        The clinical review supports enzyme activity as the direct diagnostic
        readout of IDS deficiency.
- name: Heparan sulfate and dermatan sulfate lysosomal accumulation
  description: >-
    IDS insufficiency leads to excess heparan sulfate and dermatan sulfate
    within lysosomes across multiple tissues and organs, creating the primary
    storage burden that initiates downstream disease biology.
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  chemical_entities:
  - preferred_term: heparan sulfate
    term:
      id: CHEBI:28815
      label: heparan sulfate
    modifier: INCREASED
  - preferred_term: dermatan sulfate
    term:
      id: CHEBI:18376
      label: dermatan sulfate
    modifier: INCREASED
  - preferred_term: glycosaminoglycan
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
    modifier: INCREASED
  evidence:
  - reference: PMID:21518713
    reference_title: "Natural progression of neurological disease in mucopolysaccharidosis type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder
      characterized by insufficiency of the iduronate-2-sulfatase enzyme, which
      results in excess heparan and dermatan sulfates within the lysosomes of
      various tissues and organs, including the central nervous system.
    explanation: >-
      This natural-history abstract directly supports lysosomal storage of
      heparan sulfate and dermatan sulfate as the core upstream lesion.
  downstream:
  - target: Lysosomal dysfunction
    causal_link_type: DIRECT
    description: Persistent substrate storage disrupts lysosomal homeostasis and produces broader cellular dysfunction.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In addition to the accumulation of CSF GAGs, nMPS II patients show
        elevated levels of lysosomal lipids, neurofilament light chain, and other
        biomarkers of neuronal damage and degeneration.
      explanation: >-
        Patient biomarker data support the edge from CSF GAG accumulation to
        broader lysosomal lipid abnormalities and downstream cellular injury.
  - target: Hepatosplenomegaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - visceral lysosomal storage and organ enlargement
    description: Visceral glycosaminoglycan storage contributes to enlarged liver and spleen volume.
    evidence:
    - reference: PMID:17185020
      reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Urinary glycosaminoglycans were reduced within 2 weeks of initiating
        idursulfase and were decreased 49% after 48 weeks of treatment
        (P<0.0001). Both liver and spleen volume were decreased at 24 weeks
        (P<0.01) and 48 weeks (P<0.001).
      explanation: >-
        Clinical enzyme replacement data show that lowering the GAG burden is
        accompanied by reduced liver and spleen volume, supporting the
        storage-to-organomegaly edge.
  - target: Urinary glycosaminoglycans
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - accumulated glycosaminoglycans excreted in urine
    description: >-
      Quantitative urinary glycosaminoglycan excretion is a diagnostic and
      pharmacodynamic readout of the systemic storage burden.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Sceening is by quantitative assessment of urinary GAGs excretion.
      explanation: >-
        The review supports urinary GAG excretion as a screening readout of
        Hunter syndrome storage.
    - reference: PMID:17185020
      reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001).
      explanation: >-
        Idursulfase reduction of urinary GAGs supports this readout as a
        pharmacodynamic marker of storage burden.
  - target: CSF heparan sulfate
    causal_link_type: DIRECT
    description: >-
      Heparan sulfate is elevated in CSF in neuronopathic MPS II and reflects
      central nervous system substrate accumulation.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
      explanation: >-
        Patient CSF data support elevated heparan sulfate as a central storage
        readout.
  - target: CSF dermatan sulfate
    causal_link_type: DIRECT
    description: >-
      Dermatan sulfate is also elevated in CSF in neuronopathic MPS II and
      reports the second primary IDS substrate.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
      explanation: >-
        Patient CSF data support elevated dermatan sulfate as a central storage
        readout.
- name: Lysosomal dysfunction
  description: >-
    Storage burden progresses beyond primary glycosaminoglycan accumulation to
    broader lysosomal dysfunction, including glial lysosomal aggregation in
    IDS-deficient neural cells and evidence of abnormal lysosomal lipid burden
    in neuronopathic patients.
  biological_processes:
  - preferred_term: autophagy
    modifier: DECREASED
    term:
      id: GO:0006914
      label: autophagy
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  evidence:
  - reference: PMID:24201805
    reference_title: "Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Experiments here reported show that NSCs derived from the subventricular
      zone (SVZ) of early symptomatic IDS-knockout (IDS-ko) mouse retained
      self-renewal capacity in vitro, but differentiated earlier than wild-type
      (wt) cells, displaying an evident lysosomal aggregation in
      oligodendroglial and astroglial cells.
    explanation: >-
      This in vitro IDS-knockout neural stem cell model shows direct lysosomal
      aggregation in glial lineages, supporting secondary lysosomal dysfunction
      downstream of substrate storage.
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition to the accumulation of CSF GAGs, nMPS II patients show
      elevated levels of lysosomal lipids, neurofilament light chain, and other
      biomarkers of neuronal damage and degeneration.
    explanation: >-
      Patient biomarker data show that primary storage is accompanied by
      lysosomal dysfunction in neuronopathic MPS II.
  downstream:
  - target: Secondary neuronal injury
    causal_link_type: DIRECT
    description: Persistent lysosomal dysfunction is associated with measurable neuronal damage and degeneration in neuronopathic disease.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In addition to the accumulation of CSF GAGs, nMPS II patients show
        elevated levels of lysosomal lipids, neurofilament light chain, and other
        biomarkers of neuronal damage and degeneration.
      explanation: >-
        The same patient samples link lysosomal lipid biomarkers with
        neurofilament light chain and other neuronal injury biomarkers.
  - target: CSF GM3 ganglioside
    causal_link_type: DIRECT
    description: >-
      GM3 ganglioside elevation in CSF reports secondary lysosomal lipid storage
      and dysfunction in the neuronopathic CNS branch.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Targeted analysis of GM3, BMP, and glucosylceramides shows that nMPS II patient CSF (regardless of therapy) have elevated levels of these lipids (Figure 7A,D,G), and that there is a strong correlation between HS and lipids levels in the CSF (Figure 7B,E,H).
      explanation: >-
        Targeted patient CSF lipidomics supports GM3 ganglioside as a secondary
        lysosomal dysfunction readout correlated with heparan sulfate.
  - target: Connective tissue and skeletal-muscle dysfunction
    causal_link_type: DIRECT
    description: Storage-driven cellular dysfunction propagates into joints, cartilage, growth plates, and connective tissue.
    evidence:
    - reference: PMID:20354449
      reference_title: "Mucopolysaccharidosis type II: skeletal-muscle system involvement."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Lysosomal accumulation of these GAG molecules results in cell, tissue,
        and organ dysfunction. The skeletal-muscle system involvement is because
        of essential accumulated GAGs in joints and connective tissue.
      explanation: >-
        This review explicitly links lysosomal GAG accumulation to joint and
        connective-tissue skeletal-muscle involvement.
  - target: Airway soft-tissue disease
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - glycosaminoglycan storage and thickening in upper-airway soft tissues
    description: Soft-tissue storage and thickening drive progressive upper airway disease.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recurrent and prolonged rhinitis with persistent nasal discharge are the
        first symptoms of airway disease that manifests itself as noisy breathing
        and later sleep apnea.
      explanation: >-
        The abstract supports progressive airway disease in Hunter syndrome;
        the edge is marked indirect because the soft-tissue storage intermediate
        is represented in the edge text rather than as a separate node.
  - target: Cardiac valvular thickening and dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - dermatan-sulfate-rich valve extracellular matrix
    - lifetime glycosaminoglycan burden
    description: Persistent glycosaminoglycan burden disrupts valve extracellular matrix homeostasis and drives valvular disease.
    evidence:
    - reference: PMID:39440439
      reference_title: "Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Lifetime GAG burden (calculated from urinary GAG measurements)
        correlated significantly with the degree of valve disease.
      explanation: >-
        This natural-history cohort links cumulative glycosaminoglycan burden to
        valve disease severity, supporting an indirect edge through valve matrix
        storage.
- name: Secondary neuronal injury
  description: >-
    In neuronopathic MPS II, lysosomal dysfunction is accompanied by measurable
    biomarkers of neuronal damage and degeneration, establishing a distinct
    downstream neuroinjury step before overt clinical CNS decline.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition to the accumulation of CSF GAGs, nMPS II patients show
      elevated levels of lysosomal lipids, neurofilament light chain, and other
      biomarkers of neuronal damage and degeneration.
    explanation: >-
      This patient biomarker study supports a separate downstream step of
      neuronal damage and degeneration after lysosomal dysfunction.
  downstream:
  - target: Neuronopathic central nervous system dysfunction
    causal_link_type: DIRECT
    description: Secondary neuronal injury contributes to progressive cognitive and motor decline in severe disease.
    evidence:
    - reference: PMID:21518713
      reference_title: "Natural progression of neurological disease in mucopolysaccharidosis type II."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        One subset of patients had normal cognitive, speech and language, and
        adaptive functions whereas the other showed a dramatic decline in these
        areas.
      explanation: >-
        The natural-history cohort supports progression from neuronal injury
        biology to measurable cognitive, language, and adaptive decline.
  - target: Neurofilament light chain
    causal_link_type: DIRECT
    description: >-
      Elevated neurofilament light chain in CSF and serum reports axonal injury
      and active neurodegeneration in neuronopathic MPS II.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We measured levels of Nf-L in the CSF and serum and found a significant elevation in Nf-L in both the CSF and serum of nMPS II patients regardless of their treatment regimen (Figure 8A,C), and that Nf-L levels positively correlated with CSF HS (Figure 8B).
      explanation: >-
        Patient fluid biomarker data support neurofilament light chain as a
        direct readout of secondary neuronal injury.
- name: Neuronopathic central nervous system dysfunction
  description: >-
    Severe Hunter syndrome causes progressive central nervous system disease
    with decline in cognitive, language, adaptive, and motor functions rather
    than stable neurodevelopment.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  evidence:
  - reference: PMID:21518713
    reference_title: "Natural progression of neurological disease in mucopolysaccharidosis type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One subset of patients had normal cognitive, speech and language, and
      adaptive functions whereas the other showed a dramatic decline in these
      areas.
    explanation: >-
      This natural-history study shows the neuronopathic subgroup has
      progressive central nervous system dysfunction rather than stable
      cognition.
  - reference: PMID:19597960
    reference_title: "Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with the severe form of the disease have cognitive impairment
      and typically die in the second decade of life.
    explanation: >-
      This large Hunter Outcome Survey review supports clinically meaningful
      severe neuronopathic disease with cognitive impairment and worse outcome.
  downstream:
  - target: Cognitive impairment
    causal_link_type: DIRECT
    description: The severe neuronopathic form manifests clinically as progressive cognitive impairment.
    evidence:
    - reference: PMID:19597960
      reference_title: "Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Patients with the severe form of the disease have cognitive impairment
        and typically die in the second decade of life.
      explanation: >-
        This large observational Hunter Outcome Survey review directly connects
        severe neuronopathic disease with cognitive impairment.
  - target: Hydrocephalus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - communicating hydrocephalus in the neuronopathic CNS branch
    description: >-
      Communicating hydrocephalus is a recognized CNS manifestation that can
      accompany macrocephaly in MPS II.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Additional findings in neuronopathic and non-neuronopathic MPS II
        include: short stature, macrocephaly with or without communicating
        hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
        hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
        syndrome, and hepatosplenomegaly.
      explanation: >-
        GeneReviews explicitly lists communicating hydrocephalus as a possible
        component of the MPS II cranial/CNS phenotype.
- name: Connective tissue and skeletal-muscle dysfunction
  description: >-
    Accumulated glycosaminoglycans in joints, cartilage, and connective tissue
    drive progressive stiffness, growth impairment, and skeletal pathology.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  evidence:
  - reference: PMID:20354449
    reference_title: "Mucopolysaccharidosis type II: skeletal-muscle system involvement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lysosomal accumulation of these GAG molecules results in cell, tissue,
      and organ dysfunction. The skeletal-muscle system involvement is because
      of essential accumulated GAGs in joints and connective tissue.
    explanation: >-
      This Hunter syndrome review directly links substrate storage to the joint
      and connective-tissue pathology underlying short stature and stiffness.
  - reference: PMID:38085235
    reference_title: "Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In contrast, tracheal, epiphyseal, and articular cartilage remained
      largely uncorrected by all vectors tested.
    explanation: >-
      This MPS II model shows that cartilage remains a resistant downstream
      tissue compartment even when other peripheral pathology improves, matching
      the clinical stubbornness of skeletal disease.
  downstream:
  - target: Joint stiffness
    causal_link_type: DIRECT
    description: Joint and connective-tissue GAG storage manifests clinically as progressive joint stiffness.
    evidence:
    - reference: PMID:20354449
      reference_title: "Mucopolysaccharidosis type II: skeletal-muscle system involvement."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The skeletal-muscle system involvement is because of essential
        accumulated GAGs in joints and connective tissue.
      explanation: >-
        The review links joint/connective-tissue GAG accumulation to the
        musculoskeletal branch that produces joint stiffness.
  - target: Short stature
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - skeletal changes and growth-plate/cartilage involvement
    description: Skeletal and cartilage involvement contributes to growth impairment and short stature.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Children with severe form, diagnosed at 12-36 months, have coarse facial
        feature, short stature, joint stiffness, short neck, broad chest, large
        head circumference, watery diarrhea, skeletal changes, progressive and
        profound mental retardation, retinal degeneration' hearing loss,
        cardiomyopathy, valvular involvement, with progressive thickening and
        stiffening of the valve leaflets leading to mitral and aortic
        regurgitation and stenosis .
      explanation: >-
        The clinical review lists short stature alongside joint stiffness and
        skeletal changes, supporting this endpoint from the musculoskeletal
        disease branch.
  - target: Macrocephaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cranial skeletal and communicating-hydrocephalus contributions to head size
    description: >-
      Cranial skeletal involvement and communicating hydrocephalus can manifest
      as macrocephaly or large head circumference.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Additional findings in neuronopathic and non-neuronopathic MPS II
        include: short stature, macrocephaly with or without communicating
        hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
        hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
        syndrome, and hepatosplenomegaly.
      explanation: >-
        GeneReviews lists macrocephaly with or without communicating
        hydrocephalus among additional MPS II findings.
  - target: Spinal canal stenosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - skeletal and connective-tissue narrowing of the spinal canal
    description: >-
      Skeletal and connective-tissue disease can narrow the spinal canal and
      cause spinal stenosis.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Additional findings in neuronopathic and non-neuronopathic MPS II
        include: short stature, macrocephaly with or without communicating
        hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
        hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
        syndrome, and hepatosplenomegaly.
      explanation: >-
        GeneReviews explicitly lists spinal stenosis as an MPS II manifestation.
  - target: Carpal tunnel syndrome
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - median nerve entrapment in glycosaminoglycan-thickened wrist connective tissue
    description: >-
      Connective-tissue thickening around the wrist can produce median nerve
      compression clinically recognized as carpal tunnel syndrome.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Additional findings in neuronopathic and non-neuronopathic MPS II
        include: short stature, macrocephaly with or without communicating
        hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
        hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
        syndrome, and hepatosplenomegaly.
      explanation: >-
        GeneReviews explicitly lists carpal tunnel syndrome as an MPS II
        manifestation; HPO represents this as constrictive median neuropathy.
- name: Airway soft-tissue disease
  description: >-
    Progressive rhinitis, noisy breathing, and sleep apnea reflect
    glycosaminoglycan storage in upper-airway soft tissues and related ENT
    structures.
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrent and prolonged rhinitis with persistent nasal discharge are the
      first symptoms of airway disease that manifests itself as noisy breathing
      and later sleep apnea.
    explanation: >-
      This disease-specific review abstract directly supports progressive airway
      soft-tissue disease leading to noisy breathing and sleep apnea.
  downstream:
  - target: Sleep apnea
    causal_link_type: DIRECT
    description: Progressive airway disease evolves from rhinitis and noisy breathing to sleep apnea.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recurrent and prolonged rhinitis with persistent nasal discharge are the
        first symptoms of airway disease that manifests itself as noisy breathing
        and later sleep apnea.
      explanation: >-
        The abstract explicitly states that airway disease later manifests as
        sleep apnea.
- name: Cardiac valvular thickening and dysfunction
  description: >-
    Dermatan-sulfate-rich valve extracellular matrix accumulates glycosaminoglycans,
    producing progressive leaflet thickening, regurgitation, and stenosis.
  evidence:
  - reference: PMID:39440439
    reference_title: "Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DS is a major component of the extracellular matrix of heart valves,
      which can be affected in MPS II.
    explanation: >-
      This cardiac natural-history study directly links dermatan-sulfate-rich
      valve extracellular matrix biology to the valvular disease of Hunter
      syndrome.
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      valvular involvement, with progressive thickening and stiffening of the
      valve leaflets leading to mitral and aortic regurgitation and stenosis .
    explanation: >-
      This review abstract directly describes the downstream valvular phenotype
      produced by Hunter syndrome.
  downstream:
  - target: Cardiac valve disease
    causal_link_type: DIRECT
    description: Leaflet thickening and stiffening produce the structural cardiac valve phenotype.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        valvular involvement, with progressive thickening and stiffening of the
        valve leaflets leading to mitral and aortic regurgitation and stenosis .
      explanation: >-
        The review directly connects valvular thickening and stiffening to
        clinically apparent regurgitation and stenosis.
phenotypes:
- name: Coarse facial features
  category: Craniofacial
  description: >-
    Progressive coarsening of facial appearance is a characteristic early somatic
    feature of severe Hunter syndrome.
  phenotype_term:
    preferred_term: Coarse facial features
    term:
      id: HP:0000280
      label: Coarse facial features
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with severe form, diagnosed at 12-36 months, have coarse facial
      feature, short stature, joint stiffness, short neck, broad chest, large
      head circumference, watery diarrhea, skeletal changes, progressive and
      profound mental retardation, retinal degeneration' hearing loss,
      cardiomyopathy, valvular involvement, with progressive thickening and
      stiffening of the valve leaflets leading to mitral and aortic
      regurgitation and stenosis .
    explanation: >-
      This disease-specific review lists coarse facial features among the core
      early somatic manifestations of severe Hunter syndrome.
- name: Short stature
  category: Growth
  description: >-
    Growth failure develops as connective-tissue and skeletal disease
    progresses.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with severe form, diagnosed at 12-36 months, have coarse facial
      feature, short stature, joint stiffness, short neck, broad chest, large
      head circumference, watery diarrhea, skeletal changes, progressive and
      profound mental retardation, retinal degeneration' hearing loss,
      cardiomyopathy, valvular involvement, with progressive thickening and
      stiffening of the valve leaflets leading to mitral and aortic
      regurgitation and stenosis .
    explanation: >-
      This review explicitly lists short stature as part of the severe Hunter
      phenotype.
- name: Macrocephaly
  category: Craniofacial
  description: >-
    Macrocephaly or large head circumference can occur in MPS II, sometimes in
    association with communicating hydrocephalus.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:20301451
    reference_title: Mucopolysaccharidosis Type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings in neuronopathic and non-neuronopathic MPS II
      include: short stature, macrocephaly with or without communicating
      hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
      hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
      syndrome, and hepatosplenomegaly.
    explanation: >-
      GeneReviews explicitly lists macrocephaly with or without communicating
      hydrocephalus among MPS II findings.
- name: Hydrocephalus
  category: Neurologic
  description: >-
    Communicating hydrocephalus can accompany macrocephaly in MPS II and is
    part of the recognized cranial/CNS phenotype.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:20301451
    reference_title: Mucopolysaccharidosis Type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings in neuronopathic and non-neuronopathic MPS II
      include: short stature, macrocephaly with or without communicating
      hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
      hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
      syndrome, and hepatosplenomegaly.
    explanation: >-
      GeneReviews lists communicating hydrocephalus as a possible associated
      finding with macrocephaly in MPS II.
- name: Joint stiffness
  category: Musculoskeletal
  description: >-
    Progressive joint stiffness reflects glycosaminoglycan storage in joints and
    connective tissue.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with severe form, diagnosed at 12-36 months, have coarse facial
      feature, short stature, joint stiffness, short neck, broad chest, large
      head circumference, watery diarrhea, skeletal changes, progressive and
      profound mental retardation, retinal degeneration' hearing loss,
      cardiomyopathy, valvular involvement, with progressive thickening and
      stiffening of the valve leaflets leading to mitral and aortic
      regurgitation and stenosis .
    explanation: >-
      This abstract directly lists joint stiffness among the characteristic
      somatic manifestations of severe disease.
- name: Spinal canal stenosis
  category: Musculoskeletal
  description: >-
    Spinal canal stenosis is part of the skeletal/connective-tissue burden in
    MPS II and can require neurosurgical or orthopedic management.
  phenotype_term:
    preferred_term: Spinal canal stenosis
    term:
      id: HP:0003416
      label: Spinal canal stenosis
  evidence:
  - reference: PMID:20301451
    reference_title: Mucopolysaccharidosis Type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings in neuronopathic and non-neuronopathic MPS II
      include: short stature, macrocephaly with or without communicating
      hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
      hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
      syndrome, and hepatosplenomegaly.
    explanation: >-
      GeneReviews explicitly lists spinal stenosis among additional MPS II
      findings.
- name: Carpal tunnel syndrome
  category: Neurologic
  description: >-
    Carpal tunnel syndrome reflects constrictive median neuropathy at the wrist
    and is a recognized peripheral nerve entrapment complication in MPS II.
  phenotype_term:
    preferred_term: Carpal tunnel syndrome
    term:
      id: HP:0012185
      label: Constrictive median neuropathy
  evidence:
  - reference: PMID:20301451
    reference_title: Mucopolysaccharidosis Type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings in neuronopathic and non-neuronopathic MPS II
      include: short stature, macrocephaly with or without communicating
      hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural
      hearing loss, dysostosis multiplex, spinal stenosis, carpal tunnel
      syndrome, and hepatosplenomegaly.
    explanation: >-
      GeneReviews explicitly lists carpal tunnel syndrome; HPO represents the
      syndrome as constrictive median neuropathy.
- name: Hearing impairment
  category: Otolaryngologic
  description: >-
    Hearing loss is common in severe disease and contributes to the ENT burden
    of Hunter syndrome.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with severe form, diagnosed at 12-36 months, have coarse facial
      feature, short stature, joint stiffness, short neck, broad chest, large
      head circumference, watery diarrhea, skeletal changes, progressive and
      profound mental retardation, retinal degeneration' hearing loss,
      cardiomyopathy, valvular involvement, with progressive thickening and
      stiffening of the valve leaflets leading to mitral and aortic
      regurgitation and stenosis .
    explanation: >-
      This review abstract explicitly includes hearing loss among the classic
      manifestations of severe Hunter syndrome.
- name: Sleep apnea
  category: Respiratory
  description: >-
    Progressive upper-airway disease commonly evolves into noisy breathing and
    sleep apnea.
  phenotype_term:
    preferred_term: Sleep apnea
    term:
      id: HP:0010535
      label: Sleep apnea
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrent and prolonged rhinitis with persistent nasal discharge are the
      first symptoms of airway disease that manifests itself as noisy breathing
      and later sleep apnea.
    explanation: >-
      This abstract directly supports sleep apnea as a downstream respiratory
      manifestation of progressive airway disease in Hunter syndrome.
- name: Hepatosplenomegaly
  category: Gastrointestinal
  description: >-
    Increased liver and spleen volume is part of the multisystem visceral
    storage burden of Hunter syndrome.
  phenotype_term:
    preferred_term: Hepatosplenomegaly
    term:
      id: HP:0001433
      label: Hepatosplenomegaly
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inguinal and umbilical hernias occur caused by the disturbed structure of
      connective tissue and increased liver and spleen volume.
    explanation: >-
      This disease-specific review supports hepatosplenomegaly as part of the
      visceral storage phenotype.
- name: Cardiac valve disease
  category: Cardiovascular
  description: >-
    Progressive valvular thickening causes clinically important regurgitation
    and stenosis in Hunter syndrome.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      valvular involvement, with progressive thickening and stiffening of the
      valve leaflets leading to mitral and aortic regurgitation and stenosis .
    explanation: >-
      This abstract directly supports progressive structural heart valve disease
      in Hunter syndrome.
- name: Cognitive impairment
  category: Neurologic
  description: >-
    Severe neuronopathic disease causes progressive cognitive impairment,
    whereas attenuated forms may preserve cognition.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:19597960
    reference_title: "Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with the severe form of the disease have cognitive impairment
      and typically die in the second decade of life.
    explanation: >-
      This Hunter Outcome Survey review directly supports cognitive impairment
      as a defining feature of severe neuronopathic Hunter syndrome.
biochemical:
- name: Iduronate-2-sulfatase activity
  biomarker_term:
    preferred_term: iduronate 2-sulfatase
    term:
      id: NCIT:C75606
      label: Iduronate 2-Sulfatase
  presence: DECREASED
  context: >-
    Enzyme activity assay in leukocytes, fibroblasts, or plasma is the
    diagnostic biochemical readout of IDS deficiency.
  readouts:
  - target: Iduronate-2-sulfatase deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Decreased iduronate-2-sulfatase activity reports the root lysosomal
      enzyme defect in Hunter syndrome.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Definitive diagnosis is based on enzyme activity assay in leukocytes, fibroblasts or plasma.
      explanation: >-
        The review supports enzyme activity assay as the definitive biochemical
        diagnostic readout.
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hunter syndrome is caused by deficiency of the lysososmal enzyme
      iduronate-2-sulphatase that cleaves O-linked sulphate moieties from
      dermatan sulphate and heparan sulphate and leads to accumulation of GAGs.
    explanation: >-
      This abstract supports deficient iduronate-2-sulfatase as the primary
      biochemical lesion.
- name: Urinary glycosaminoglycans
  biomarker_term:
    preferred_term: glycosaminoglycan
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  presence: ABNORMAL
  context: >-
    Urinary glycosaminoglycan excretion is used for screening and falls rapidly
    with idursulfase, making it both a diagnostic and pharmacodynamic storage
    readout.
  readouts:
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Abnormal urinary GAG excretion reports systemic glycosaminoglycan storage.
    evidence:
    - reference: PMID:25345092
      reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Sceening is by quantitative assessment of urinary GAGs excretion.
      explanation: >-
        The review names quantitative urinary GAG excretion as the screening
        readout.
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    interpretation: >-
      Falling urinary GAGs report treatment-lowered systemic storage burden.
    evidence:
    - reference: PMID:17185020
      reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001).
      explanation: >-
        The idursulfase trial directly supports urinary GAG reduction as a
        pharmacodynamic treatment readout.
  evidence:
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sceening is by quantitative assessment of urinary GAGs excretion.
    explanation: >-
      This supports urinary GAGs as a Hunter syndrome biochemical screening
      readout.
- name: CSF heparan sulfate
  biomarker_term:
    preferred_term: heparan sulfate
    term:
      id: CHEBI:28815
      label: heparan sulfate
  presence: INCREASED
  context: >-
    Heparan sulfate is markedly elevated in CSF from neuronopathic MPS II
    patients despite standard peripheral therapy.
  readouts:
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated CSF heparan sulfate reports CNS substrate storage in
      neuronopathic disease.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
      explanation: >-
        Patient CSF measurements directly support elevated heparan sulfate.
  evidence:
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
    explanation: >-
      This supports CSF heparan sulfate as an elevated neuronopathic MPS II
      biomarker.
- name: CSF dermatan sulfate
  biomarker_term:
    preferred_term: dermatan sulfate
    term:
      id: CHEBI:18376
      label: dermatan sulfate
  presence: INCREASED
  context: >-
    Dermatan sulfate is markedly elevated in CSF from neuronopathic MPS II
    patients and complements heparan sulfate as an IDS-substrate readout.
  readouts:
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated CSF dermatan sulfate reports CNS substrate storage in
      neuronopathic disease.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
      explanation: >-
        Patient CSF measurements directly support elevated dermatan sulfate.
  evidence:
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we observed a significant, 11-fold and 30-fold elevation in HS and DS levels, respectively in nMPS II patient CSF relative to the control group (Figure 4A,B).
    explanation: >-
      This supports CSF dermatan sulfate as an elevated neuronopathic MPS II
      biomarker.
- name: CSF GM3 ganglioside
  biomarker_term:
    preferred_term: ganglioside GM3
    term:
      id: CHEBI:84118
      label: ganglioside GM3
  presence: INCREASED
  context: >-
    GM3 ganglioside is a secondary lysosomal lipid biomarker elevated in CSF
    from neuronopathic MPS II patients and correlated with CSF heparan sulfate.
  readouts:
  - target: Lysosomal dysfunction
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated CSF GM3 reports secondary lysosomal lipid storage beyond primary
      GAG accumulation.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Targeted analysis of GM3, BMP, and glucosylceramides shows that nMPS II patient CSF (regardless of therapy) have elevated levels of these lipids (Figure 7A,D,G), and that there is a strong correlation between HS and lipids levels in the CSF (Figure 7B,E,H).
      explanation: >-
        Targeted lipidomics supports GM3 as a secondary lysosomal dysfunction
        readout.
  evidence:
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Targeted analysis of GM3, BMP, and glucosylceramides shows that nMPS II patient CSF (regardless of therapy) have elevated levels of these lipids (Figure 7A,D,G), and that there is a strong correlation between HS and lipids levels in the CSF (Figure 7B,E,H).
    explanation: >-
      This supports CSF GM3 ganglioside elevation as a fluid biomarker of
      lysosomal dysfunction.
- name: Neurofilament light chain
  biomarker_term:
    preferred_term: neurofilament light chain
    term:
      id: NCIT:C88043
      label: Neurofilament Light Polypeptide
  presence: INCREASED
  context: >-
    Neurofilament light chain is elevated in CSF and serum from neuronopathic
    MPS II patients and reports neuronal injury downstream of lysosomal
    dysfunction.
  readouts:
  - target: Secondary neuronal injury
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated neurofilament light chain reports active axonal injury and
      neurodegeneration in the CNS disease branch.
    evidence:
    - reference: PMID:32707880
      reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We measured levels of Nf-L in the CSF and serum and found a significant elevation in Nf-L in both the CSF and serum of nMPS II patients regardless of their treatment regimen (Figure 8A,C), and that Nf-L levels positively correlated with CSF HS (Figure 8B).
      explanation: >-
        Patient CSF and serum data support neurofilament light chain as a
        neuronal injury readout.
  evidence:
  - reference: PMID:32707880
    reference_title: "Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We measured levels of Nf-L in the CSF and serum and found a significant elevation in Nf-L in both the CSF and serum of nMPS II patients regardless of their treatment regimen (Figure 8A,C), and that Nf-L levels positively correlated with CSF HS (Figure 8B).
    explanation: >-
      This supports neurofilament light chain as a fluid biomarker of neuronal
      injury in neuronopathic MPS II.
genetic:
- name: IDS
  gene_term:
    preferred_term: IDS
    term:
      id: hgnc:5389
      label: IDS
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_753ba7a6-cef5-4665-81e9-306e11c618c5-2018-02-21T110000.000Z
    reference_title: "IDS / mucopolysaccharidosis type 2 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IDS | HGNC:5389 | mucopolysaccharidosis type 2 | MONDO:0010674 | XL | Definitive"
    explanation: ClinGen classifies the IDS-mucopolysaccharidosis type 2 gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Idursulfase enzyme replacement therapy
  description: >-
    Intravenous recombinant iduronate-2-sulfatase is the standard
    disease-modifying therapy for peripheral somatic disease. It lowers urinary
    glycosaminoglycans, reduces organomegaly, and can improve endurance, but
    treatment effects are incomplete and CNS disease is not corrected.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: idursulfase
      term:
        id: NCIT:C65883
        label: Idursulfase
  target_mechanisms:
  - target: Iduronate-2-sulfatase deficiency
    treatment_effect: RESTORES
    description: Recombinant IDS supplements the deficient lysosomal enzyme in peripheral tissues.
    evidence:
    - reference: PMID:17185020
      reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        To evaluate the safety and explore the efficacy of idursulfase
        (recombinant human iduronate-2-sulfatase) treatment for
        mucopolysaccharidosis II (MPS II).
      explanation: >-
        The clinical trial identifies idursulfase as recombinant human IDS,
        supporting treatment replacement of the deficient enzyme.
  - target: Heparan sulfate and dermatan sulfate lysosomal accumulation
    treatment_effect: INHIBITS
    description: Enzyme replacement lowers peripheral glycosaminoglycan burden and reduces visceral storage.
    evidence:
    - reference: PMID:17185020
      reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Urinary glycosaminoglycans were reduced within 2 weeks of initiating
        idursulfase and were decreased 49% after 48 weeks of treatment
        (P<0.0001).
      explanation: >-
        The trial directly shows that idursulfase lowers glycosaminoglycan
        burden, supporting inhibition of the storage mechanism.
  evidence:
  - reference: PMID:17185020
    reference_title: "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Urinary glycosaminoglycans were reduced within 2 weeks of initiating
      idursulfase and were decreased 49% after 48 weeks of treatment
      (P<0.0001). Both liver and spleen volume were decreased at 24 weeks
      (P<0.01) and 48 weeks (P<0.001). The 6-minute walk test distance
      increased an average of 48 meters after 48 weeks (P=0.013).
    explanation: >-
      This phase I/II trial directly supports biochemical and somatic benefit
      from idursulfase therapy.
  - reference: PMID:25231261
    reference_title: "Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although the present protocol of idursulfase administration may result
      efficacious in delaying the MPS II somatic disease progression at some
      extent, in this study we observed that several signs and symptoms did not
      improve during the therapy.
    explanation: >-
      This independent long-term pediatric study supports a conservative
      treatment claim: idursulfase delays somatic progression, but responses are
      partial rather than globally corrective.
  - reference: PMID:25345092
    reference_title: "Mucopolysaccharidosis type II, Hunter's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Current research is focused on pharmacological chaperones, gene therapy
      and substrate reduction therapy and therapies that, unlike Idursulfase, do
      cross the blood-brain barrier.
    explanation: >-
      This review supports the clinically important limitation that standard
      intravenous idursulfase does not address CNS disease because it does not
      cross the blood-brain barrier.
- name: Tividenofusp alfa-eknm enzyme replacement therapy
  description: >-
    Tividenofusp alfa-eknm is a CNS-penetrant enzyme replacement therapy
    approved for MPS II, extending enzyme replacement to the neuronopathic
    disease branch that standard intravenous idursulfase does not adequately
    address.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tividenofusp alfa-eknm
      term:
        id: NCIT:C199121
        label: Tividenofusp Alfa
  target_mechanisms:
  - target: Iduronate-2-sulfatase deficiency
    treatment_effect: RESTORES
    description: >-
      CNS-penetrant enzyme replacement is intended to restore deficient
      iduronate-2-sulfatase activity beyond the peripheral compartment.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Weekly enzyme replacement therapy (ERT) with infusions of idursulfase,
        a recombinant form of human I2S, or tividenofusp alfa-eknm, a
        CNS-penetrant ERT, are approved for individuals with MPS II.
      explanation: >-
        GeneReviews identifies tividenofusp alfa-eknm as an approved
        CNS-penetrant ERT for MPS II.
  - target: Secondary neuronal injury
    treatment_effect: INHIBITS
    description: >-
      Brain-penetrant enzyme replacement is mechanistically directed at the CNS
      injury branch downstream of lysosomal storage.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Weekly enzyme replacement therapy (ERT) with infusions of idursulfase,
        a recombinant form of human I2S, or tividenofusp alfa-eknm, a
        CNS-penetrant ERT, are approved for individuals with MPS II.
      explanation: >-
        The CNS-penetrant designation supports linking this approved ERT to the
        neuronopathic injury branch.
  - target: Neuronopathic central nervous system dysfunction
    treatment_effect: INHIBITS
    description: >-
      CNS penetration directly addresses the neuronopathic branch that
      non-BBB-crossing idursulfase does not adequately treat.
    evidence:
    - reference: PMID:20301451
      reference_title: Mucopolysaccharidosis Type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Weekly enzyme replacement therapy (ERT) with infusions of idursulfase,
        a recombinant form of human I2S, or tividenofusp alfa-eknm, a
        CNS-penetrant ERT, are approved for individuals with MPS II.
      explanation: >-
        GeneReviews states that tividenofusp alfa-eknm is CNS penetrant and
        approved for individuals with MPS II.
  evidence:
  - reference: PMID:20301451
    reference_title: Mucopolysaccharidosis Type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Weekly enzyme replacement therapy (ERT) with infusions of idursulfase, a
      recombinant form of human I2S, or tividenofusp alfa-eknm, a CNS-penetrant
      ERT, are approved for individuals with MPS II.
    explanation: >-
      GeneReviews supports tividenofusp alfa-eknm as an approved CNS-penetrant
      enzyme replacement therapy for MPS II.
- name: Multidisciplinary supportive care
  description: >-
    Hunter syndrome remains a high-burden multisystem disease even in treated
    adults, so ongoing respiratory, ENT/audiologic, orthopedic, cardiology, and
    surgical management is required alongside disease-directed therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  - preferred_term: Sleep apnea
    term:
      id: HP:0010535
      label: Sleep apnea
  - preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
  - preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  - preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  - preferred_term: Spinal canal stenosis
    term:
      id: HP:0003416
      label: Spinal canal stenosis
  - preferred_term: Carpal tunnel syndrome
    term:
      id: HP:0012185
      label: Constrictive median neuropathy
  evidence:
  - reference: PMID:40598289
    reference_title: "Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall, adult patients with neuronopathic and non-neuronopathic MPS II
      had a high disease burden and requirement for surgeries, emphasizing the
      need to continue multidisciplinary management and regular assessments in
      adulthood.
    explanation: >-
      This Hunter Outcome Survey analysis supports ongoing symptom-directed,
      multidisciplinary management as a necessary component of care even in the
      modern treatment era.
references:
- reference: PMID:20301451
  title: Mucopolysaccharidosis Type II.
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

1
PMID:20301451
Mucopolysaccharidosis Type II.
No top-level findings curated for this source.

Deep Research

1
Hunter syndrome manual research note ▸

Hunter syndrome manual research note

Date: 2026-04-14

Scope

Manual curation note for a demo-ready disease-level dismech entry for Hunter syndrome (mucopolysaccharidosis type 2, MPS II), with emphasis on a fully connected mechanism graph, exact PMID-backed quotes, honest evidence-source tagging, and conservative treatment claims.

Naming and grounding checks

  • Monarch / MONDO check:
  • MONDO:0010674 resolves to primary label mucopolysaccharidosis type 2.
  • Monarch exact synonyms include Hunter syndrome, Hunter's syndrome, MPS II, and iduronate 2-sulfatase deficiency.

  • Curation choice: file name and display name use the familiar clinical name Hunter syndrome, while disease_term.term.label stays exactly on the MONDO primary label mucopolysaccharidosis type 2.

  • ClinGen check:

  • ClinGen gene validity entry for IDS maps to mucopolysaccharidosis type 2 / MONDO:0010674.
  • Local cache row: "IDS","HGNC:5389","mucopolysaccharidosis type 2","MONDO:0010674","XL","SOP5","Definitive",...
  • Direct ClinGen page grep confirms the key fields: IDS, mucopolysaccharidosis type 2, MONDO:0010674, X-linked, Definitive.
  • Curation choice: frame the proximal lesion explicitly as IDS / iduronate-2-sulfatase deficiency and keep the inheritance claim strictly X-linked recessive.

Curation decisions

  • Included one disease-modifying treatment entry: Idursulfase enzyme replacement therapy. Reason: standard of care with direct human clinical trial evidence. Structured therapeutic agent term verified locally against the repo OAK NCIT adapter as NCIT:C65883 / Idursulfase.

  • Included one downstream management entry: Multidisciplinary supportive care. Reason: conservative, clinically coherent, and supported by Hunter Outcome Survey adult-burden data.

  • Did not include hematopoietic stem cell transplantation as a standard treatment entry. Reason: available abstract-level evidence is limited, mixed, and not strong enough for a clean conservative standard-of-care statement in Hunter syndrome.

  • Did not use dysostosis multiplex as a Hunter-specific phenotype entry. Reason: the selected Hunter-specific abstract set gave strong support for short stature, joint stiffness, and connective-tissue/joint disease, but not a clean exact Hunter-specific abstract quote explicitly naming dysostosis multiplex.

Mechanism graph used in YAML

  1. Iduronate-2-sulfatase deficiency
  2. Heparan sulfate and dermatan sulfate lysosomal accumulation
  3. Lysosomal dysfunction
  4. Secondary neuronal injury
  5. Neuronopathic central nervous system dysfunction
  6. Connective tissue and skeletal-muscle dysfunction
  7. Airway soft-tissue disease
  8. Cardiac valvular thickening and dysfunction

Graph logic:

  • IDS deficiency directly causes heparan sulfate and dermatan sulfate storage.
  • Storage burden progresses into broader lysosomal dysfunction.
  • Lysosomal dysfunction feeds a separate secondary neuronal injury node before overt neuronopathic CNS dysfunction, while also branching into the major non-CNS tissue-level outcomes needed for a clinically coherent Hunter syndrome graph: connective tissue / skeletal disease, airway disease, and valve disease.
  • Idursulfase targets the proximal enzyme deficiency and the substrate-storage node.
  • Supportive care targets downstream phenotype burden rather than upstream biochemistry.

Selected exact-quote evidence set

Core disease framing

  • PMID:25345092
  • Source type: HUMAN_CLINICAL
  • Quote: Hunter syndrome is caused by deficiency of the lysososmal enzyme iduronate-2-sulphatase that cleaves O-linked sulphate moieties from dermatan sulphate and heparan sulphate and leads to accumulation of GAGs.

  • Use: proximal enzyme defect and substrate specificity.

  • PMID:25345092

  • Source type: HUMAN_CLINICAL
  • Quote: The disease is a X-linked condition affecting males and rarely females, clinically divided into severe (2/3) and attenuated types.

  • Use: inheritance and severe/attenuated framing.

  • PMID:21518713

  • Source type: HUMAN_CLINICAL
  • Quote: Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by insufficiency of the iduronate-2-sulfatase enzyme, which results in excess heparan and dermatan sulfates within the lysosomes of various tissues and organs, including the central nervous system.
  • Use: storage node.

Lysosomal dysfunction and CNS disease

  • PMID:24201805
  • Source type: IN_VITRO
  • Quote: Experiments here reported show that NSCs derived from the subventricular zone (SVZ) of early symptomatic IDS-knockout (IDS-ko) mouse retained self-renewal capacity in vitro, but differentiated earlier than wild-type (wt) cells, displaying an evident lysosomal aggregation in oligodendroglial and astroglial cells.

  • Use: secondary lysosomal dysfunction in glial lineages.

  • PMID:32707880

  • Source type: HUMAN_CLINICAL
  • Quote: In addition to the accumulation of CSF GAGs, nMPS II patients show elevated levels of lysosomal lipids, neurofilament light chain, and other biomarkers of neuronal damage and degeneration.

  • Use: human evidence for downstream lysosome dysfunction and neuronal injury.

  • PMID:21518713

  • Source type: HUMAN_CLINICAL
  • Quote: One subset of patients had normal cognitive, speech and language, and adaptive functions whereas the other showed a dramatic decline in these areas.

  • Use: neuronopathic CNS decline.

  • PMID:19597960

  • Source type: HUMAN_CLINICAL
  • Quote: Patients with the severe form of the disease have cognitive impairment and typically die in the second decade of life.
  • Use: severe-form cognitive impairment phenotype and clinical severity.

Connective tissue, airway, and cardiac tissue-level dysfunction

  • PMID:20354449
  • Source type: HUMAN_CLINICAL
  • Quote: Lysosomal accumulation of these GAG molecules results in cell, tissue, and organ dysfunction. The skeletal-muscle system involvement is because of essential accumulated GAGs in joints and connective tissue.

  • Use: connective-tissue / skeletal-muscle node.

  • PMID:38085235

  • Source type: MODEL_ORGANISM
  • Quote: In contrast, tracheal, epiphyseal, and articular cartilage remained largely uncorrected by all vectors tested.

  • Use: cartilage as a resistant downstream tissue compartment.

  • PMID:25345092

  • Source type: HUMAN_CLINICAL
  • Quote: Recurrent and prolonged rhinitis with persistent nasal discharge are the first symptoms of airway disease that manifests itself as noisy breathing and later sleep apnea.

  • Use: airway soft-tissue disease and sleep apnea phenotype.

  • PMID:39440439

  • Source type: HUMAN_CLINICAL
  • Quote: DS is a major component of the extracellular matrix of heart valves, which can be affected in MPS II.

  • Use: cardiac valve mechanism node.

  • PMID:25345092

  • Source type: HUMAN_CLINICAL
  • Quote: valvular involvement, with progressive thickening and stiffening of the valve leaflets leading to mitral and aortic regurgitation and stenosis .
  • Use: valvular phenotype.

Phenotype support chosen for YAML

  • PMID:25345092 supports:
  • coarse facial features
  • short stature
  • joint stiffness
  • hearing impairment
  • sleep apnea
  • hepatosplenomegaly

  • cardiac valve disease

  • PMID:19597960 and PMID:21518713 support:

  • cognitive impairment / neuronopathic severe disease

Treatment support chosen for YAML

  • PMID:17185020
  • Source type: HUMAN_CLINICAL
  • Quote: Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P<0.0001). Both liver and spleen volume were decreased at 24 weeks (P<0.01) and 48 weeks (P<0.001). The 6-minute walk test distance increased an average of 48 meters after 48 weeks (P=0.013).

  • Use: direct human efficacy of idursulfase on somatic burden.

  • PMID:25231261

  • Source type: HUMAN_CLINICAL
  • Quote: Although the present protocol of idursulfase administration may result efficacious in delaying the MPS II somatic disease progression at some extent, in this study we observed that several signs and symptoms did not improve during the therapy.

  • Use: conservative limitation on idursulfase claims.

  • PMID:25345092

  • Source type: HUMAN_CLINICAL
  • Quote: Current research is focused on pharmacological chaperones, gene therapy and substrate reduction therapy and therapies that, unlike Idursulfase, do cross the blood-brain barrier.

  • Use: conservative statement that standard idursulfase does not address CNS disease.

  • PMID:40598289

  • Source type: HUMAN_CLINICAL
  • Quote: Overall, adult patients with neuronopathic and non-neuronopathic MPS II had a high disease burden and requirement for surgeries, emphasizing the need to continue multidisciplinary management and regular assessments in adulthood.
  • Use: justify supportive multidisciplinary care without overstating disease modification.